These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21177320)

  • 21. Emerging oral drugs for multiple sclerosis.
    Gasperini C; Cefaro LA; Borriello G; Tosto G; Prosperini L; Pozzilli C
    Expert Opin Emerg Drugs; 2008 Sep; 13(3):465-77. PubMed ID: 18764723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics.
    Leist TP; Marks S
    Neurology; 2010 Jan; 74 Suppl 1():S54-61. PubMed ID: 20038764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral treatment for multiple sclerosis.
    Killestein J; Rudick RA; Polman CH
    Lancet Neurol; 2011 Nov; 10(11):1026-34. PubMed ID: 22014437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?
    Goodin DS
    Ann Neurol; 2006 Apr; 59(4):597-605. PubMed ID: 16566022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study.
    Mesaros S; Rocca M; Sormani M; Valsasina P; Markowitz C; De Stefano N; Montalban X; Barkhof F; Ranjeva J; Sailer M; Kappos L; Comi G; Filippi M
    Mult Scler; 2010 Mar; 16(3):325-31. PubMed ID: 20086023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Grey matter atrophy in patients suffering from multiple sclerosis.
    Kincses ZT; Tóth E; Bankó N; Veréb D; Szabó N; Csete G; Faragó P; Király A; Bencsik K; Vécsei L
    Ideggyogy Sz; 2014 Sep; 67(9-10):293-300. PubMed ID: 25518257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
    Yeh EA; Weinstock-Guttman B
    Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunotherapy of multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials].
    Ozawa K; Saida T
    Rinsho Shinkeigaku; 1995 Dec; 35(12):1501-3. PubMed ID: 8752444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.
    Ghezzi A; Rocca MA; Baroncini D; Annovazzi P; Zaffaroni M; Minonzio G; Comi G; Filippi M
    J Neurol; 2013 Jan; 260(1):327-9. PubMed ID: 23161460
    [No Abstract]   [Full Text] [Related]  

  • 30. Dealing with excess of zeros in the statistical analysis of magnetic resonance imaging lesion count in multiple sclerosis.
    Francois M; Peter C; Gordon F
    Pharm Stat; 2012; 11(5):417-24. PubMed ID: 22888087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fingolimod for multiple sclerosis.
    Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defining interferon beta response status in multiple sclerosis patients.
    Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
    Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.
    Sormani MP; Bonzano L; Roccatagliata L; Cutter GR; Mancardi GL; Bruzzi P
    Ann Neurol; 2009 Mar; 65(3):268-75. PubMed ID: 19334061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumefactive multiple sclerosis lesions under fingolimod treatment.
    Visser F; Wattjes MP; Pouwels PJ; Linssen WH; van Oosten BW
    Neurology; 2012 Nov; 79(19):2000-3. PubMed ID: 23035065
    [No Abstract]   [Full Text] [Related]  

  • 35. Multiple sclerosis therapeutic pipeline: opportunities and challenges.
    Krieger S
    Mt Sinai J Med; 2011; 78(2):192-206. PubMed ID: 21425264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Principles of a new treatment algorithm in multiple sclerosis.
    Hartung HP; Montalban X; Sorensen PS; Vermersch P; Olsson T
    Expert Rev Neurother; 2011 Mar; 11(3):351-62. PubMed ID: 21375441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
    Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; Amato MP; De Stefano N
    Neurology; 2009 Aug; 73(7):498-503. PubMed ID: 19641173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Avoiding infusion therapy prime benefit of new MS drug.
    Morrow T
    Manag Care; 2010 Aug; 19(8):49-50. PubMed ID: 20822073
    [No Abstract]   [Full Text] [Related]  

  • 39. Fingolimod. Mitsubishi Pharma/Novartis.
    Dumont FJ
    IDrugs; 2005 Mar; 8(3):236-53. PubMed ID: 15772896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.